Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 29Nivolumab 29Specimen Handling 24Ipilimumab 19Magnetic Resonance Spectroscopy 17Biopsy 11CTLA-4 Antigen 9Opdualag 8Cyclophosphamide 8relatlimab 6Paclitaxel 6trametinib 5fludarabine 5cemiplimab 5Carboplatin 5fludarabine phosphate 4dabrafenib 4binimetinib 4avelumab 4HhAntag691 4lifileucel 3capivasertib 3atezolizumab 3aldesleukin 3X-Rays 3Temozolomide 3Taxes 3Surgical Procedures, Operative 3Standard of Care 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Toll-Like Receptor 1 × Dermatologic × 30 days × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡